Download Files:
Products Details
Product Description
– TRK-IN-17 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3)[1].
Web ID
– HY-146523
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C21H21F2N7S
References
– [1]Nicola ROBAS, et al. Pharmaceutical compositions and their uses. Patent WO2021148807A1.
CAS Number
– 2409544-80-3
Molecular Weight
– 441.50
SMILES
– CCN/C(C1=CN=C2C=CC(N3C[C@H](C[C@@H]3C4=CC(F)=CC(SC)=C4)F)=NN12)=NC#N
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Trk Receptor
Pathway
– Neuronal Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
